NALIRIFOX in the frontline for metastatic pancreatic cancer: evidence beyond NAPOLI 3.
0/5 보강
APA
Wainberg ZA, M O'Reilly E (2024). NALIRIFOX in the frontline for metastatic pancreatic cancer: evidence beyond NAPOLI 3.. Nature reviews. Clinical oncology, 21(12), 900-901. https://doi.org/10.1038/s41571-024-00952-5
MLA
Wainberg ZA, et al.. "NALIRIFOX in the frontline for metastatic pancreatic cancer: evidence beyond NAPOLI 3.." Nature reviews. Clinical oncology, vol. 21, no. 12, 2024, pp. 900-901.
PMID
39455872
같은 제1저자의 인용 많은 논문 (5)
- Neoadjuvant modified FOLFIRINOX plus nivolumab in borderline-resectable pancreatic ductal adenocarcinoma: a pilot phase 1 trial.
- Quemliclustat and chemotherapy with or without zimberelimab in metastatic pancreatic adenocarcinoma: a randomized phase 1 trial.
- A plain language summary of NALIRIFOX compared with nab-paclitaxel and gemcitabine for patients with metastatic pancreatic cancer (NAPOLI 3).
- Lymph node-targeted, mKRAS-specific amphiphile vaccine in pancreatic and colorectal cancer: phase 1 AMPLIFY-201 trial final results.
- Health-related quality of life with bemarituzumab plus mFOLFOX6 in patients with FGFR2b-overexpressing, advanced gastric or gastroesophageal junction cancer.